Human brain endothelial cells endeavor to immunoregulate CD8 T cells via PD-1 ligand expression in multiple sclerosis

Journal of Neuroinflammation

Volumn 8, Issue , 2011, Pages

  Pittet, Camille L ^a   Newcombe, Jia ^b   Prat, Alexandre ^a,c   Arbour, Nathalie ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c NOTRE DAME HOSPITAL   (Canada)

Author keywords

B7 molecules; Blood brain barrier; Cd8 t cells; Endothelial cells; Pd l1; Pd l2

Indexed keywords

PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; CD274 PROTEIN, HUMAN; CYTOKINE; PDCD1 PROTEIN, HUMAN; PDCD1LG2 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ADULT; AGED; ARTICLE; BRAIN BLOOD VESSEL; BRAIN TISSUE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN BRAIN ENDOTHELIAL CELL; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOREGULATION; LYMPHOCYTE MIGRATION; MALE; MULTIPLE SCLEROSIS; PROTEIN EXPRESSION; UPREGULATION; BLOOD BRAIN BARRIER; BRAIN; CELL CULTURE; CELL PROLIFERATION; CYTOLOGY; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MIDDLE AGED; PATHOLOGY; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION; VASCULARIZATION;

ADULT; AGED; ANTIGENS, CD274; BLOOD-BRAIN BARRIER; BRAIN; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; COCULTURE TECHNIQUES; CYTOKINES; ENDOTHELIAL CELLS; FEMALE; HUMANS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PROGRAMMED CELL DEATH 1 LIGAND 2 PROTEIN; PROGRAMMED CELL DEATH 1 RECEPTOR; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION;

EID: 80455158264     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-8-155     Document Type: Article

References (45)

1. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005, 23:683-747. 10.1146/annurev.immunol.23.021704.115707, 15771584.
2. Persidsky Y, Ramirez SH, Haorah J, Kanmogne GD. Blood-brain barrier: structural components and function under physiologic and pathologic conditions. J Neuroimmune Pharmacol 2006, 1:223-236. 10.1007/s11481-006-9025-3, 18040800.
3. Alvarez JI, Cayrol R, Prat A. Disruption of central nervous system barriers in multiple sclerosis. Biochim Biophys Acta 2011, 1812:252-264.
4. Friese MA, Fugger L. Autoreactive CD8+ T cells in multiple sclerosis: a new target for therapy?. Brain 2005, 128:1747-1763. 10.1093/brain/awh578, 15975943.
5. Mars LT, Saikali P, Liblau RS, Arbour N. Contribution of CD8 T lymphocytes to the immuno-pathogenesis of multiple sclerosis and its animal models. Biochim Biophys Acta 2010, 1812:151-161.
6. Melzer N, Meuth SG, Wiendl H. CD8+ T cells and neuronal damage: direct and collateral mechanisms of cytotoxicity and impaired electrical excitability. FASEB J 2009, 23:3659-3673. 10.1096/fj.09-136200, 19567369.
7. Hauser SL, Bhan AK, Gilles F, Kemp M, Kerr C, Weiner HL. Immunohistochemical analysis of the cellular infiltrate in multiple sclerosis lesions. Ann Neurol 1986, 19:578-587. 10.1002/ana.410190610, 3524414.
8. Neumann H, Medana IM, Bauer J, Lassmann H. Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases. Trends Neurosci 2002, 25:313-319. 10.1016/S0166-2236(02)02154-9, 12086750.
9. Lassmann H. Recent neuropathological findings in MS--implications for diagnosis and therapy. J Neurol 2004, 251(Suppl 4):IV2-5.
10. Gay FW, Drye TJ, Dick GW, Esiri MM. The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis. Identification and characterization of the primary demyelinating lesion. Brain 1997, 120:1461-1483. 10.1093/brain/120.8.1461, 9278635.
11. Babbe H, Roers A, Waisman A, Lassmann H, Goebels N, Hohlfeld R, Friese M, Schroder R, Deckert M, Schmidt S, et al. Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med 2000, 192:393-404. 10.1084/jem.192.3.393, 2193223, 10934227.
12. Gotsman I, Grabie N, Dacosta R, Sukhova G, Sharpe A, Lichtman AH. Proatherogenic immune responses are regulated by the PD-1/PD-L pathway in mice. J Clin Invest 2007, 117:2974-2982. 10.1172/JCI31344, 1974866, 17853943.
13. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000, 192:1027-1034. 10.1084/jem.192.7.1027, 2193311, 11015443.
14. Carter L, Fouser LA, Jussif J, Fitz L, Deng B, Wood CR, Collins M, Honjo T, Freeman GJ, Carreno BM. PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Eur J Immunol 2002, 32:634-643. 10.1002/1521-4141(200203)32:3<634::AID-IMMU634>3.0.CO;2-9, 11857337.
15. Rodig N, Ryan T, Allen JA, Pang H, Grabie N, Chernova T, Greenfield EA, Liang SC, Sharpe AH, Lichtman AH, Freeman GJ. Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis. Eur J Immunol 2003, 33:3117-3126. 10.1002/eji.200324270, 14579280.
16. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008, 26:677-704. 10.1146/annurev.immunol.26.021607.090331, 18173375.
17. Pittet CL, Newcombe J, Antel JP, Arbour N. The majority of infiltrating CD8 T lymphocytes in multiple sclerosis lesions is insensitive to enhanced PD-L1 levels on CNS cells. Glia 2011, 59:841-856. 10.1002/glia.21158, 21360758.
18. Ansari MJ, Salama AD, Chitnis T, Smith RN, Yagita H, Akiba H, Yamazaki T, Azuma M, Iwai H, Khoury SJ, et al. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 2003, 198:63-69. 10.1084/jem.20022125, 2196083, 12847137.
19. Yang W, Li H, Chen PW, Alizadeh H, He Y, Hogan RN, Niederkorn JY. PD-L1 expression on human ocular cells and its possible role in regulating immune-mediated ocular inflammation. Invest Ophthalmol Vis Sci 2009, 50:273-280.
20. Sugita S, Usui Y, Horie S, Futagami Y, Yamada Y, Ma J, Kezuka T, Hamada H, Usui T, Mochizuki M, Yamagami S. Human corneal endothelial cells expressing programmed death-ligand 1 (PD-L1) suppress PD-1+ T helper 1 cells by a contact-dependent mechanism. Invest Ophthalmol Vis Sci 2009, 50:263-272.
21. Grabie N, Gotsman I, DaCosta R, Pang H, Stavrakis G, Butte MJ, Keir ME, Freeman GJ, Sharpe AH, Lichtman AH. Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heart. Circulation 2007, 116:2062-2071. 10.1161/CIRCULATIONAHA.107.709360, 17938288.
22. LaGier AJ, Pober JS. Immune accessory functions of human endothelial cells are modulated by overexpression of B7-H1 (PDL1). Hum Immunol 2006, 67:568-578. 10.1016/j.humimm.2006.04.013, 16916652.
23. Mazanet MM, Hughes CC. B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis. J Immunol 2002, 169:3581-3588.
24. Zhu B, Guleria I, Khosroshahi A, Chitnis T, Imitola J, Azuma M, Yagita H, Sayegh MH, Khoury SJ. Differential role of programmed death-ligand 1 [corrected] and programmed death-ligand 2 [corrected] in regulating the susceptibility and chronic progression of experimental autoimmune encephalomyelitis. J Immunol 2006, 176:3480-3489.
25. Kroner A, Schwab N, Ip CW, Ortler S, Gobel K, Nave KA, Maurer M, Martini R, Wiendl H. Accelerated course of experimental autoimmune encephalomyelitis in PD-1-deficient central nervous system myelin mutants. Am J Pathol 2009, 174:2290-2299. 10.2353/ajpath.2009.081012, 2684193, 19443704.
26. Salama AD, Chitnis T, Imitola J, Ansari MJ, Akiba H, Tushima F, Azuma M, Yagita H, Sayegh MH, Khoury SJ. Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J Exp Med 2003, 198:71-78. 10.1084/jem.20022119, 2196082, 12847138.
27. Kroner A, Schwab N, Ip CW, Leder C, Nave KA, Maurer M, Wiendl H, Martini R. PD-1 regulates neural damage in oligodendroglia-induced inflammation. PLoS One 2009, 4:e4405. 10.1371/journal.pone.0004405, 2635015, 19197390.
28. Prat A, Biernacki K, Pouly S, Nalbantoglu J, Couture R, Antel JP. Kinin B1 receptor expression and function on human brain endothelial cells. J Neuropathol Exp Neurol 2000, 59:896-906.
29. Arbour N, Lapointe R, Saikali P, McCrea E, Regen T, Antel JP. A new clinically relevant approach to expand myelin specific T cells. J Immunol Methods 2006, 310:53-61. 10.1016/j.jim.2005.12.009, 16464465.
30. Saikali P, Antel JP, Newcombe J, Chen Z, Freedman M, Blain M, Cayrol R, Prat A, Hall JA, Arbour N. NKG2D-mediated cytotoxicity toward oligodendrocytes suggests a mechanism for tissue injury in multiple sclerosis. J Neurosci 2007, 27:1220-1228. 10.1523/JNEUROSCI.4402-06.2007, 17267578.
31. Arbour N, Holz A, Sipe JC, Naniche D, Romine JS, Zyroff J, Oldstone MB. A new approach for evaluating antigen-specific T cell responses to myelin antigens during the course of multiple sclerosis. J Neuroimmunol 2003, 137:197-209. 10.1016/S0165-5728(03)00080-8, 12667664.
32. Li H, Cuzner ML, Newcombe J. Microglia-derived macrophages in early multiple sclerosis plaques. Neuropathol Appl Neurobiol 1996, 22:207-215. 10.1111/j.1365-2990.1996.tb00896.x, 8804022.
33. Ifergan I, Wosik K, Cayrol R, Kebir H, Auger C, Bernard M, Bouthillier A, Moumdjian R, Duquette P, Prat A. Statins reduce human blood-brain barrier permeability and restrict leukocyte migration: relevance to multiple sclerosis. Ann Neurol 2006, 60:45-55. 10.1002/ana.20875, 16729291.
34. Ifergan I, Kebir H, Alvarez JI, Marceau G, Bernard M, Bourbonnière L, Poirier J, Duquette P, Talbot PJ, Arbour N, Prat A. Central nervous system recruitment of effector memory CD8+ T lymphocytes during neuroinflammation is dependent on a4 integrin. Brain 2011,
35. Saunders PA, Hendrycks VR, Lidinsky WA, Woods ML. PD-L2:PD-1 involvement in T cell proliferation, cytokine production, and integrin-mediated adhesion. Eur J Immunol 2005, 35:3561-3569. 10.1002/eji.200526347, 16278812.
36. Fife BT, Pauken KE. The role of the PD-1 pathway in autoimmunity and peripheral tolerance. Ann N Y Acad Sci 2011, 1217:45-59. 10.1111/j.1749-6632.2010.05919.x, 21276005.
37. Brown JA, Dorfman DM, Ma FR, Sullivan EL, Munoz O, Wood CR, Greenfield EA, Freeman GJ. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol 2003, 170:1257-1266.
38. Cheng X, Dai H, Wan N, Moore Y, Vankayalapati R, Dai Z. Interaction of programmed death-1 and programmed death-1 ligand-1 contributes to testicular immune privilege. Transplantation 2009, 87:1778-1786. 10.1097/TP.0b013e3181a75633, 19543053.
39. El Annan J, Goyal S, Zhang Q, Freeman GJ, Sharpe AH, Dana R. Regulation of T-cell chemotaxis by programmed death-ligand 1 (PD-L1) in dry eye-associated corneal inflammation. Invest Ophthalmol Vis Sci 2010, 51:3418-3423. 10.1167/iovs.09-3684, 20019373.
40. Schreiner B, Bailey SL, Shin T, Chen L, Miller SD. PD-1 ligands expressed on myeloid-derived APC in the CNS regulate T-cell responses in EAE. Eur J Immunol 2008, 38:2706-2717. 10.1002/eji.200838137, 2727707, 18825752.
41. Grauer OM, Wesseling P, Adema GJ. Immunotherapy of diffuse gliomas: biological background, current status and future developments. Brain Pathol 2009, 19:674-693. 10.1111/j.1750-3639.2009.00315.x, 19744040.
42. Liang SC, Latchman YE, Buhlmann JE, Tomczak MF, Horwitz BH, Freeman GJ, Sharpe AH. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol 2003, 33:2706-2716. 10.1002/eji.200324228, 14515254.
43. Kaku H, Rothstein TL. Octamer binding protein 2 (Oct2) regulates PD-L2 gene expression in B-1 cells through lineage-specific activity of a unique, intronic promoter. Genes Immun 2010, 11:55-66. 10.1038/gene.2009.68, 2809120, 19710692.
44. Lesterhuis WJ, Punt CJ, Hato SV, Eleveld-Trancikova D, Jansen BJ, Nierkens S, Schreibelt G, de Boer A, Van Herpen CM, Kaanders JH, et al. Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. J Clin Invest 2011,
45. Wulff H, Calabresi PA, Allie R, Yun S, Pennington M, Beeton C, Chandy KG. The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS. J Clin Invest 2003, 111:1703-1713. 156104, 12782673.